View in EDS

N-protein vaccine is effective against COVID-19: Phase 3, randomized, double-blind, placebo-controlled clinical trial.

Saved in:
Bibliographic Details
Title: N-protein vaccine is effective against COVID-19: Phase 3, randomized, double-blind, placebo-controlled clinical trial.
Authors: Rabdano SO; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia. Electronic address: sevastyan@rabdano.ru., Ruzanova EA; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Vertyachikh AE; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Teplykh VA; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Emelyanova AB; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Rudakov GO; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Arakelov SA; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Pletyukhina IV; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Saveliev NS; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Lukovenko AA; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Fakhretdinova LN; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Safi AS; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Zhirenkina EN; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Polyakova IN; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Belozerova NS; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Klykov VV; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Savelieva AP; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Ekimov AA; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Pokachalov KV; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Merkulov VA; I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; Centre for Evaluation and Control of Finished Pharmaceutical Products, Federal State Budgetary Institution 'Scientific Centre for Expert Evaluation of Medicinal Products' of the Ministry of Health of the Russian Federation, Moscow, Russia., Yudin SM; Centre for Strategic Planning of FMBA of Russia Federal State Budgetary Institution 'Centre for Strategic Planning and Management of Biomedical Health Risks' of the Federal Medical Biological Agency, Moscow, Russia., Kruchko DS; Federal Medical-Biological Agency of Russia, Moscow, Russia., Berzin IA; Federal Medical-Biological Agency of Russia, Moscow, Russia., Skvortsova VI; Federal Medical-Biological Agency of Russia, Moscow, Russia.
Corporate Authors: Clinical Trial Group
Source: The Journal of infection [J Infect] 2024 Nov; Vol. 89 (5), pp. 106288. Date of Electronic Publication: 2024 Sep 26.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study
Journal Info: Publisher: W.B. Saunders Country of Publication: England NLM ID: 7908424 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-2742 (Electronic) Linking ISSN: 01634453 NLM ISO Abbreviation: J Infect Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39341405
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: N-protein vaccine is effective against COVID-19: Phase 3, randomized, double-blind, placebo-controlled clinical trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Rabdano+SO%22">Rabdano SO</searchLink>; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia. Electronic address: sevastyan@rabdano.ru.<br /><searchLink fieldCode="AU" term="%22Ruzanova+EA%22">Ruzanova EA</searchLink>; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia.<br /><searchLink fieldCode="AU" term="%22Vertyachikh+AE%22">Vertyachikh AE</searchLink>; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia.<br /><searchLink fieldCode="AU" term="%22Teplykh+VA%22">Teplykh VA</searchLink>; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia.<br /><searchLink fieldCode="AU" term="%22Emelyanova+AB%22">Emelyanova AB</searchLink>; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia.<br /><searchLink fieldCode="AU" term="%22Rudakov+GO%22">Rudakov GO</searchLink>; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia.<br /><searchLink fieldCode="AU" term="%22Arakelov+SA%22">Arakelov SA</searchLink>; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia.<br /><searchLink fieldCode="AU" term="%22Pletyukhina+IV%22">Pletyukhina IV</searchLink>; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia.<br /><searchLink fieldCode="AU" term="%22Saveliev+NS%22">Saveliev NS</searchLink>; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia.<br /><searchLink fieldCode="AU" term="%22Lukovenko+AA%22">Lukovenko AA</searchLink>; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia.<br /><searchLink fieldCode="AU" term="%22Fakhretdinova+LN%22">Fakhretdinova LN</searchLink>; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia.<br /><searchLink fieldCode="AU" term="%22Safi+AS%22">Safi AS</searchLink>; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia.<br /><searchLink fieldCode="AU" term="%22Zhirenkina+EN%22">Zhirenkina EN</searchLink>; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia.<br /><searchLink fieldCode="AU" term="%22Polyakova+IN%22">Polyakova IN</searchLink>; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia.<br /><searchLink fieldCode="AU" term="%22Belozerova+NS%22">Belozerova NS</searchLink>; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia.<br /><searchLink fieldCode="AU" term="%22Klykov+VV%22">Klykov VV</searchLink>; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia.<br /><searchLink fieldCode="AU" term="%22Savelieva+AP%22">Savelieva AP</searchLink>; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia.<br /><searchLink fieldCode="AU" term="%22Ekimov+AA%22">Ekimov AA</searchLink>; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia.<br /><searchLink fieldCode="AU" term="%22Pokachalov+KV%22">Pokachalov KV</searchLink>; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia.<br /><searchLink fieldCode="AU" term="%22Merkulov+VA%22">Merkulov VA</searchLink>; I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; Centre for Evaluation and Control of Finished Pharmaceutical Products, Federal State Budgetary Institution 'Scientific Centre for Expert Evaluation of Medicinal Products' of the Ministry of Health of the Russian Federation, Moscow, Russia.<br /><searchLink fieldCode="AU" term="%22Yudin+SM%22">Yudin SM</searchLink>; Centre for Strategic Planning of FMBA of Russia Federal State Budgetary Institution 'Centre for Strategic Planning and Management of Biomedical Health Risks' of the Federal Medical Biological Agency, Moscow, Russia.<br /><searchLink fieldCode="AU" term="%22Kruchko+DS%22">Kruchko DS</searchLink>; Federal Medical-Biological Agency of Russia, Moscow, Russia.<br /><searchLink fieldCode="AU" term="%22Berzin+IA%22">Berzin IA</searchLink>; Federal Medical-Biological Agency of Russia, Moscow, Russia.<br /><searchLink fieldCode="AU" term="%22Skvortsova+VI%22">Skvortsova VI</searchLink>; Federal Medical-Biological Agency of Russia, Moscow, Russia.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22Clinical+Trial+Group%22">Clinical Trial Group</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227908424%22">The Journal of infection</searchLink> [J Infect] 2024 Nov; Vol. 89 (5), pp. 106288. <i>Date of Electronic Publication: </i>2024 Sep 26.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22W%2EB%2E+Saunders%22">W.B. Saunders </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>7908424 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1532-2742 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201634453%22">01634453 </searchLink><i>NLM ISO Abbreviation: </i>J Infect <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39341405
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jinf.2024.106288
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 106288
    Titles:
      – TitleFull: N-protein vaccine is effective against COVID-19: Phase 3, randomized, double-blind, placebo-controlled clinical trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Rabdano SO
      – PersonEntity:
          Name:
            NameFull: Ruzanova EA
      – PersonEntity:
          Name:
            NameFull: Vertyachikh AE
      – PersonEntity:
          Name:
            NameFull: Teplykh VA
      – PersonEntity:
          Name:
            NameFull: Emelyanova AB
      – PersonEntity:
          Name:
            NameFull: Rudakov GO
      – PersonEntity:
          Name:
            NameFull: Arakelov SA
      – PersonEntity:
          Name:
            NameFull: Pletyukhina IV
      – PersonEntity:
          Name:
            NameFull: Saveliev NS
      – PersonEntity:
          Name:
            NameFull: Lukovenko AA
      – PersonEntity:
          Name:
            NameFull: Fakhretdinova LN
      – PersonEntity:
          Name:
            NameFull: Safi AS
      – PersonEntity:
          Name:
            NameFull: Zhirenkina EN
      – PersonEntity:
          Name:
            NameFull: Polyakova IN
      – PersonEntity:
          Name:
            NameFull: Belozerova NS
      – PersonEntity:
          Name:
            NameFull: Klykov VV
      – PersonEntity:
          Name:
            NameFull: Savelieva AP
      – PersonEntity:
          Name:
            NameFull: Ekimov AA
      – PersonEntity:
          Name:
            NameFull: Pokachalov KV
      – PersonEntity:
          Name:
            NameFull: Merkulov VA
      – PersonEntity:
          Name:
            NameFull: Yudin SM
      – PersonEntity:
          Name:
            NameFull: Kruchko DS
      – PersonEntity:
          Name:
            NameFull: Berzin IA
      – PersonEntity:
          Name:
            NameFull: Skvortsova VI
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: 2024 Nov
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1532-2742
          Numbering:
            – Type: volume
              Value: 89
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: The Journal of infection
              Type: main
ResultId 1